How to Use Statins in Secondary Prevention of Atherosclerotic Diseases: from the Beneficial Early Initiation to the Potentially Unfavorable Discontinuation.
Nikolaos P E KadoglouMarianna StasinopoulouPublished in: Cardiovascular drugs and therapy (2021)
Statins, a class of lipid-lowering drugs, reduce morbidity and mortality in patients with established atherosclerosis-related cardiovascular disease. Early initiation of statin therapy after admission for acute coronary syndromes (ACS), stroke, or transient ischemic attack (TIA) is associated with improved cardiovascular outcomes. Moreover, high-dose statin treatment prior to coronary or carotid revascularization has been shown to reduce cardiovascular events in these patients. However, many patients may be undertreated, and a residual cardiovascular risk remains in current clinical practice. Despite the beneficial role of statins, their discontinuation rate among patients is still elevated leading to severe adverse cardiovascular events due to atherosclerotic plaque destabilization. In this review, we summarized the impact of statin treatment among patients, focusing on the initiation time-points as well as the potential harm derived by their discontinuation.
Keyphrases
- cardiovascular disease
- cardiovascular events
- coronary artery disease
- end stage renal disease
- acute coronary syndrome
- newly diagnosed
- ejection fraction
- percutaneous coronary intervention
- chronic kidney disease
- type diabetes
- clinical practice
- prognostic factors
- stem cells
- coronary artery bypass grafting
- early onset
- atrial fibrillation
- low dose
- cardiovascular risk factors
- coronary artery
- risk assessment
- oxidative stress
- antiplatelet therapy
- stem cell transplantation